Our fourth quarter results was driven largely by a 69 basis point sequential expansion in gross margin as we leveraged a modest increase in sales to the gross profit line. As reflected in our gross margin expansion, the wave of important generic drugs with patent exclusivity has begun to take form, and we remain very excited about the opportunity generic drug introductions represent for both Omnicare and its customers.Read the rest of this transcript for free on seekingalpha.com
Omnicare CEO Discusses Q4 2011 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.